Technical Analysis for RETA - Reata Pharmaceuticals, Inc. - Class A

Grade Last Price % Change Price Change
grade A 89.49 -2.32% -2.13
RETA closed down 2.32 percent on Monday, May 20, 2019, on 87 percent of normal volume.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent Up Up Flat
See historical RETA trend table...

Date Alert Name Type % Chg
Multiple of Ten Bearish Other 0.00%
Outside Day Range Expansion 0.00%
Overbought Stochastic Strength 0.00%
Down 3 Days in a Row Weakness 0.00%
Stochastic Sell Signal Bearish -2.32%
Narrow Range Bar Range Contraction -2.32%
NR7 Range Contraction -2.32%
Upper Bollinger Band Walk Strength -2.32%
Multiple of Ten Bullish Other -2.32%
Overbought Stochastic Strength -2.32%

Older signals for RETA ...

Get a Trading Assistant

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:
Profile
Reata Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on identifying, developing, and commercializing product candidates that modulate the activity of key regulatory proteins involved in the biology of mitochondrial function, oxidative stress, and inflammation to address the unmet medical needs of patients with various serious or life-threatening diseases. The company focuses on drugs with novel mechanisms of action that modulate regulatory proteins called transcription factors. Its lead product candidates include bardoxolone methyl and RTA 408, which are members of a class of small molecules called antioxidant inflammation modulators. It is involved in LARIAT, a Phase II study of bardoxolone methyl for the treatment of pulmonary arterial hypertension and pulmonary hypertension due to interstitial lung disease. RTA 408 is in Phase II clinical development for the treatment of multiple diseases, including Friedreich's ataxia and mitochondrial myopathies. Reata Pharmaceuticals, Inc. was formerly known as Reata Discovery, Inc. and changed its name to Reata Pharmaceuticals, Inc. in May 2005. The company was founded in 2002 and is headquartered in Irving, Texas.
Medicine Diseases Inflammation Health Care Pulmonary Arterial Hypertension Pulmonary Hypertension Myopathy Friedreich's Ataxia Interstitial Lung Disease
Is RETA a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 3 bullish, 0 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 104.53
52 Week Low 30.76
Average Volume 214,919
200-Day Moving Average 75.8702
50-Day Moving Average 86.8108
20-Day Moving Average 84.566
10-Day Moving Average 89.267
Average True Range 4.7398
ADX 22.74
+DI 20.9228
-DI 12.7834
Chandelier Exit (Long, 3 ATRs ) 80.6906
Chandelier Exit (Short, 3 ATRs ) 90.0294
Upper Bollinger Band 95.2385
Lower Bollinger Band 73.8935
Percent B (%b) 0.73
BandWidth 25.24064
MACD Line 1.9007
MACD Signal Line 0.8201
MACD Histogram 1.0806
Fundamentals Value
Market Cap 2.34 Billion
Num Shares 26.1 Million
EPS -1.06
Price-to-Earnings (P/E) Ratio -84.42
Price-to-Sales 15.55
Price-to-Book 0.00
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 95.55
Resistance 3 (R3) 95.89 94.21 94.54
Resistance 2 (R2) 94.21 92.67 94.04 94.20
Resistance 1 (R1) 91.85 91.71 91.01 91.51 93.87
Pivot Point 90.17 90.17 89.75 90.00 90.17
Support 1 (S1) 87.81 88.63 86.97 87.47 85.11
Support 2 (S2) 86.13 87.67 85.96 84.78
Support 3 (S3) 83.77 86.13 84.44
Support 4 (S4) 83.43